ArticlemAbs
Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins.bioRxiv : the preprint server for biology · 2026Article
- Generation and Characterization of Bispecific VHH-Derived Surrogate Agonists Mimicking the Function of IL-18.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Clinical Development of Bispecific Antibodies: Review, Advances, and Challenges in Hematological Malignancies.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Engineering multi-specific nano-antibodies for cancer immunotherapy.Nature biomedical engineering · 2025Article
- Review
- Optimizing asymmetric antibody purification: a semi-automated process and its digital integration.mAbs · 2025Article
- Enhancing NK cell-mediated tumor killing of B7-H6Molecular therapy. Oncology · 2025Article
- Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3.Frontiers in immunology · 2025Article
- Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.Human vaccines & immunotherapeutics · 2024Article
- On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality.Protein science : a publication of the Protein Society · 2024Article
- A Generic Approach for Miniaturized Unbiased High-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody-Drug Conjugates.International journal of molecular sciences · 2024Article
- Design and engineering of bispecific antibodies: insights and practical considerations.Frontiers in bioengineering and biotechnology · 2024Review
- Topographical distribution and morphology of SP-IR axons in the antrum, pylorus, and duodenum of mice.Autonomic neuroscience : basic & clinical · 2023Article
- Review
- NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.Protein science : a publication of the Protein Society · 2023Article
- AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification ofFrontiers in molecular biosciences · 2023Article
- When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.Theranostics · 2023Review
- Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.Cancers · 2022Review
- VInternational journal of molecular sciences · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.